• The specific situation of the patient. Unless otherwise provided for by national regulations,
off-label use of medication should be limited to situations where it is in the patient's interest …

Despite overwhelming epidemiological evidence, the contribution of hypertension (HTN) to
heart failure (HF) development has been undermined in current clinical practice. This is …

Sodium-glucose co-transporters (SGLTs) in the kidneys play a pivotal role in glucose
reabsorption. Several clinical and population-based studies revealed the beneficial effects …

Heart failure (HF) is a clinical syndrome resulting from left ventricular systolic and diastolic
dysfunction, leading to significant morbidity and mortality worldwide. Despite improvements …

Sodium-glucose cotransporter 2 inhibitors (SGLT2i) are currently available for the
management of type 2 diabetes mellitus. SGLT2i acts by inhibiting renal SGLT2, thereby …

Arterial hypertension (HTN) is one of the major global contributors to cardiovascular
diseases and premature mortality, particularly due to its impact on vital organs and the …

People living with resistant hypertension (RH) are at high risk of adverse cardiovascular
events. The British and Irish Hypertension Society has identified suspected RH as a …

Heart failure (HF) remains a major cause of morbidity and mortality worldwide. Recently,
significant advances have been made in its treatment; however, diuretics remain the …

The sodium-glucose cotransporter 2 (SGLT2) is a glucose transporter that is located within
the proximal tubule of the kidney's nephrons. While it is typically associated with the kidney …

Background Sodium/glucose co-transporter 2 (SGLT2) inhibitors have transformed heart
failure (HF) treatment, offering sympatholytic effects whose mechanisms are not fully …